Physician profile

Antonio D Edwards

Family Medicine · Plaquemine, LA

NPI 1568515419

$2,609.24

in general payments reported to CMS, 2019-2025

20 companies · none reported in 2025

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$44.84

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $546.48 2019-2021
Lilly USA, LLC $488.94 2019-2023 Emgality, Jardiance, Mounjaro
Indivior INC. $237.20 2019-2022
Abbvie INC. $223.57 2021-2022
Boehringer Ingelheim Pharmaceuticals, INC. $195.68 2019-2022
Allergan, INC. $175.12 2019-2020
Novo Nordisk INC $146.50 2019-2021
Avanir Pharmaceuticals, INC. $139.01 2021
Smith+Nephew, INC. $122.11 2019
Currax Pharmaceuticals LLC $89.54 2020-2021
Novartis Pharmaceuticals Corporation $76.07 2019-2022
Ironshore Pharmaceuticals INC. $33.67 2019
Glaxosmithkline, LLC. $20.12 2021
Gilead Sciences, INC. $19.74 2020
Pfizer INC. $17.42 2022
Show all 20 companies
CompanyGeneral paymentsYearsTop products
Global Blood Therapeutics, INC. $17.26 2020
Eisai INC. $16.50 2022
Amgen INC. $16.27 2020
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $14.90 2020
Takeda Pharmaceuticals U.S.A., INC. $13.14 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$150.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Antonio D Edwards

$2,609.24

in general payments reported 2019-2025

Years
2019-2023
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/252811/antonio-d-edwards

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.